| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -446,444 | -266,031 |
| Stock-based compensation | 115,711 | 78,446 |
| Amortization of discount on marketable debt securities, net | 3,484 | 2,780 |
| Depreciation and amortization | 26,215 | 17,609 |
| Non-cash royalty revenue | 74,419 | 49,508 |
| Non-cash interest expense on liabilities for sales of future royalties | 42,531 | 28,383 |
| Other | 2,693 | 2,420 |
| Accounts receivable | -2,834 | 2,591 |
| Inventory | 6,150 | 555 |
| Prepaid expenses and other assets | 7,260 | 17,165 |
| Accounts payable, accrued, and other liabilities | -13,012 | -58,136 |
| Net cash used in operating activities | -366,171 | -274,748 |
| Purchase of property, plant, and equipment | 5,062 | 3,784 |
| Purchase of marketable debt securities | 32,445 | 15,503 |
| Proceeds from sale of marketable debt securities | 143 | 143 |
| Proceeds from maturities of marketable debt securities | 361,884 | 226,297 |
| Payments for intangible asset | 15,000 | 15,000 |
| Other | 1,273 | 1,088 |
| Net cash provided by (used in) investing activities | 308,247 | 191,065 |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | 0 | 0 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | 79,728 | 79,728 |
| Proceeds from the issuance of common stock under equity plan awards, net of tax | -4,080 | -4,078 |
| Proceeds from issuance of equity from noncontrolling interest | 0 | - |
| Net cash provided by financing activities | 83,808 | 83,806 |
| Effect of exchange rate changes on cash | 4,656 | 4,362 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,540 | 4,485 |
| Cash and cash equivalents at beginning of period | 184,159 | - |
| Cash and cash equivalents at end of period | 214,699 | - |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)